Peter Jensen has become a non-executive director of New Milton, UK-based Genetix. He is currently chairman of the European Business Forum, a non-executive director of Domino Printing Sciences, and a non-executive of Newmarket Racecourses Trust. Prior to that, he was a member of the GlaxoSmithKline integration planning committee, president of SmithKlineBeecham’s worldwide supply operations, and chairman of SmithKlineBeecham’s European consumer healthcare operations.
Genetix supplies automated systems and services for genomic and proteomic research.
Whaijen Soo has been appointed senior vice president for medical research at Biogen, based in Cambridge, Mass. He will oversee all medical research activities and will serve as a member of the research and development management team. He most recently served as vice president for clinical sciences at Roche. Soo holds a BS in Chemistry from the National Taiwan University and a PhD in Biochemistry from the University of California at Berkeley. He attended medical school at the University of California at San Francisco and did his residency at Brigham and Woman’s Hospital, Harvard Medical School.
Biogen also named Bob Hamm senior vice president of North American commercial operations. In this newly created position, Hamm will oversee Biogen’s US neurology and dermatology business units, US commercial services, and Canadian operations. Hamm joined Biogen in 1994 as associate director for logistics and has served in various positions.